Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with ...

Researchers at Imperial College London have discovered that an unusual DNA structure could be key to reversing chemotherapy ...

BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Biotech company VarmX has received clearance from the US FDA to begin a phase 3 trial of its lead candidate, VMX-C001, in ...

The Government is set to amend UK medical devices regulations by adopting EU Common Specifications for high-risk in vitro ...

Osivax has released phase 2a trial data confirming that its broad-spectrum flu vaccine candidate, OVX836, can be safely ...